X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (18392) 18392
Newspaper Article (2921) 2921
Book Chapter (770) 770
Newsletter (701) 701
Web Resource (118) 118
Magazine Article (49) 49
Transcript (23) 23
Trade Publication Article (18) 18
Book / eBook (17) 17
Book Review (3) 3
Dissertation (2) 2
Government Document (1) 1
Publication (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (14828) 14828
humans (14331) 14331
life sciences & biomedicine (14161) 14161
lymphomas (10335) 10335
oncology (8187) 8187
male (7608) 7608
female (7243) 7243
hematology (7142) 7142
cancer (5350) 5350
middle aged (5221) 5221
adult (4903) 4903
chemotherapy (4551) 4551
aged (3945) 3945
leukemia (3634) 3634
lymphoma (3431) 3431
care and treatment (3297) 3297
antineoplastic combined chemotherapy protocols - therapeutic use (3101) 3101
treatment outcome (2947) 2947
non-hodgkin's lymphomas (2715) 2715
research (2561) 2561
adolescent (2550) 2550
patients (2464) 2464
t cells (2372) 2372
prognosis (2359) 2359
animals (2267) 2267
child (2133) 2133
clinical trials (2110) 2110
tumors (2047) 2047
health aspects (1995) 1995
stem cells (1975) 1975
medicine & public health (1934) 1934
transplantation (1888) 1888
cancer therapies (1851) 1851
antineoplastic agents - therapeutic use (1828) 1828
apoptosis (1754) 1754
drug therapy (1733) 1733
analysis (1688) 1688
immunology (1654) 1654
hemic and lymphatic diseases (1576) 1576
lymphocytes (1557) 1557
rituximab (1467) 1467
medical research (1457) 1457
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (1441) 1441
child, preschool (1438) 1438
retrospective studies (1437) 1437
young adult (1418) 1418
bone marrow (1405) 1405
aged, 80 and over (1397) 1397
immunotherapy (1340) 1340
risk factors (1298) 1298
proteins (1256) 1256
medical prognosis (1211) 1211
pediatrics (1206) 1206
gene expression (1190) 1190
drug dosages (1165) 1165
disease-free survival (1155) 1155
genetic aspects (1152) 1152
diagnosis (1132) 1132
cell line, tumor (1114) 1114
mice (1106) 1106
medicine (1101) 1101
recurrence (1095) 1095
pharmaceutical industry (1083) 1083
hematology, oncology and palliative medicine (1040) 1040
kinases (1021) 1021
multiple myeloma (1011) 1011
remission induction (995) 995
pathology (992) 992
combined modality therapy (991) 991
antineoplastic combined chemotherapy protocols - administration & dosage (990) 990
studies (989) 989
abridged index medicus (987) 987
lymphocytes b (985) 985
fda approval (975) 975
lymphoma, non-hodgkin - drug therapy (967) 967
mutation (958) 958
development and progression (929) 929
lymphocytes t (913) 913
antigens (910) 910
infant (906) 906
antineoplastic agents (902) 902
cyclophosphamide - administration & dosage (888) 888
pharmacology & pharmacy (877) 877
follow-up studies (868) 868
antineoplastic combined chemotherapy protocols - adverse effects (863) 863
flow cytometry (860) 860
survival analysis (853) 853
antimitotic agents (850) 850
hematopoietic stem cells (822) 822
vincristine - administration & dosage (817) 817
transplants & implants (816) 816
cytotoxicity (810) 810
biopsy (805) 805
acute lymphocytic leukemia (804) 804
survival rate (803) 803
hematopoietic stem cell transplantation (800) 800
research article (796) 796
dermatology (786) 786
review (767) 767
antineoplastic agents - pharmacology (766) 766
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22862) 22862
Japanese (75) 75
Chinese (52) 52
German (37) 37
French (19) 19
Portuguese (14) 14
Russian (11) 11
Spanish (11) 11
Italian (10) 10
Polish (10) 10
Dutch (2) 2
Hungarian (2) 2
Korean (2) 2
Turkish (2) 2
Croatian (1) 1
Nauru (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
British journal of haematology, ISSN 0007-1048, 03/2015, Volume 168, Issue 6, pp. 811 - 819
...‐angiogenic properties. An open label, multicentre study was conducted in patients with peripheral T‐cell lymphoma (PTCL) or cutaneous T‐cell lymphoma (CTCL) who failed... 
belinostat | peripheral T cell Lymphoma | mycosis fungoides | T cell lymphoma | histone deacetylase inhibitors | Mycosis fungoides | Peripheral T cell Lymphoma | Histone deacetylase inhibitors | Belinostat | Life Sciences & Biomedicine | Hematology | Science & Technology | Recurrence | Humans | Hydroxamic Acids - adverse effects | Middle Aged | Histone Deacetylase Inhibitors - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Lymphoma, T-Cell, Cutaneous - drug therapy | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Hydroxamic Acids - administration & dosage | Adult | Female | Lymphoma, T-Cell, Peripheral - drug therapy | Drug Administration Schedule | Treatment Outcome | Lymphoma, T-Cell, Cutaneous - pathology | Sulfonamides - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Sulfonamides - adverse effects | Hydroxamic Acids - therapeutic use | Aged | Histone Deacetylase Inhibitors - therapeutic use | Infusions, Intravenous | Neoplasm Staging | Histone Deacetylase Inhibitors - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Care and treatment | Relapse | Clinical trials | Skin | Non-Hodgkin's lymphomas | Antineoplastic agents | T cells | Diseases | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 1, pp. 104 - 110
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects | Index Medicus
Journal Article
Journal of hematology and oncology, ISSN 1756-8722, 01/2014, Volume 7, Issue 1, pp. 11 - 11
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 7, pp. 1174 - 1183
Journal Article
Journal Article